symbol |
GRTS |
会社名 | Gritstone Oncology Inc (グリットスト―ン・オンコロジ―) |
分野(sector) |
Health Care
ヘルスケア
|
産業(industry) |
Biotechnology: Biological Products (No Diagnostic Substances)
|
業種 |
医薬品
医療関連(Health Care)
|
概要 |
事業概要 Gritstone Oncology Inc. is an immuno-oncology company that develops tumor-specific cancer immunotherapies to fight multiple cancer types. The Company focuses to identify and deploy therapeutic neo-antigens from individual patients' tumors to develop treatments for lung cancer. It provides Gritstone EDGE which is a tumor-specific neo-antigen (TSNA) prediction platform that predicts the presence of a patient’s TSNA on tumor cells. It also develops and manufactures a patient-specific therapeutic to direct a robust thymus (T) cell response to those TSNA predicted to be presented on the patient’s tumor. In its GRANITE-001 product candidate each of the viral prime and RNA boost immunizations contain a patient-specific set of predicted TSNA and the viral prime and RNA boost in its SLATE product candidate series contains a fixed TSNA cassette that is designed for the subset of patients with tumor neoantigens. グリットスト―ン・オンコロジ―は米国の新薬開発企業。AI技術を利用したがん治療のパイプラインを開発。各患者の腫瘍の個々の性質に焦点を当て、同社のAIプラットフォ―ムGritstone EDGEの予測能力を組み合わせることにより、複数のタイプのがんと闘う患者向けに個人化免疫療法を開発、提供する。本社所在地はカリフォルニア州エメリ―ビル。
|
本社所在地 | 5858 Horton Street Suite 210 Emeryville CA 94608 USA |
代表者氏名 | Andrew R. Allen アンドリュー・R・アレン |
代表者役職名 | President Chief Executive Officer Co-Founder Director |
電話番号 | +1 510-871-6100 |
設立年月日 | 42217 |
市場名 | NASDAQ National Market System |
ipoyear | 2018年 |
従業員数 | 100人 |
url | www.gritstoneoncology.com |
nasdaq_url | https://www.nasdaq.com/symbol/grts |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -53.00400 |
終値(lastsale) | 11.88 |
時価総額(marketcap) | 0 |
時価総額 | 時価総額(百万ドル) 423.78200 |
売上高 | 売上高(百万ドル) 0.00000 |
企業価値(EV) | 企業価値(EV)(百万ドル) 535.66500 |
当期純利益 | 当期純利益(百万ドル) -55.66800 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Gritstone Oncology Inc revenues was not reported. Net loss increased 98% to $28.8M. Higher net loss reflects Research and development - Bala increase from $11.5M to $23.5M (expense) General and administrative - increase of 57% to $4.3M (expense) Stock-based Compensation in SGA increase from $111K to $578K (expense). |